Cargando…

AB004. New technology and therapy for bladder cancer

Urothelial carcinoma of the bladder remains a significant oncologic problem throughout the world and is a source of both morbidity and mortality. Despite advances in the understanding of disease and recent molecular data from The Cancer Genome Atlas, the clinical management of disease has not fundam...

Descripción completa

Detalles Bibliográficos
Autor principal: Meng, Max
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4842617/
http://dx.doi.org/10.21037/tau.2016.s004
_version_ 1782428556047941632
author Meng, Max
author_facet Meng, Max
author_sort Meng, Max
collection PubMed
description Urothelial carcinoma of the bladder remains a significant oncologic problem throughout the world and is a source of both morbidity and mortality. Despite advances in the understanding of disease and recent molecular data from The Cancer Genome Atlas, the clinical management of disease has not fundamentally changed over the past decade. In this lecture, we will discuss (I) new technology in the detection and monitoring of non-invasive disease (blue-light and narrow band imaging); (II) the role of lymphadenectomy at the time of cystectomy; (III) a novel risk stratification tool predicting prognosis after cystectomy; and (IV) systemic therapies and clinical trials for advanced and refractory disease.
format Online
Article
Text
id pubmed-4842617
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-48426172016-05-09 AB004. New technology and therapy for bladder cancer Meng, Max Transl Androl Urol Plenary Session Urothelial carcinoma of the bladder remains a significant oncologic problem throughout the world and is a source of both morbidity and mortality. Despite advances in the understanding of disease and recent molecular data from The Cancer Genome Atlas, the clinical management of disease has not fundamentally changed over the past decade. In this lecture, we will discuss (I) new technology in the detection and monitoring of non-invasive disease (blue-light and narrow band imaging); (II) the role of lymphadenectomy at the time of cystectomy; (III) a novel risk stratification tool predicting prognosis after cystectomy; and (IV) systemic therapies and clinical trials for advanced and refractory disease. AME Publishing Company 2016-04 /pmc/articles/PMC4842617/ http://dx.doi.org/10.21037/tau.2016.s004 Text en 2016 Translational Andrology and Urology. All rights reserved.
spellingShingle Plenary Session
Meng, Max
AB004. New technology and therapy for bladder cancer
title AB004. New technology and therapy for bladder cancer
title_full AB004. New technology and therapy for bladder cancer
title_fullStr AB004. New technology and therapy for bladder cancer
title_full_unstemmed AB004. New technology and therapy for bladder cancer
title_short AB004. New technology and therapy for bladder cancer
title_sort ab004. new technology and therapy for bladder cancer
topic Plenary Session
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4842617/
http://dx.doi.org/10.21037/tau.2016.s004
work_keys_str_mv AT mengmax ab004newtechnologyandtherapyforbladdercancer